CAR-T & Cellular Therapy

Chemotherapy: the backbone of lymphoma treatment

VJHemOnc is excited to present the latest developments in the role of chemotherapy across lymphomas

The role of MRD in multiple myeloma

VJHemOnc is pleased to bring you a feature exploring the emerging applications of MRD in multiple myeloma.

Novel agents in MDS

VJHemOnc is pleased to bring you a feature exploring the latest advances and developments in novel agents for MDS, with…

Biological therapy in NHL: treating with CAR-T versus BiTEs

VJHemOnc is pleased to bring you a feature exploring the latest developments in the treatment of NHL, with leading experts…

Betibeglogene autotemcel receives FDA approval for patients with transfusion-dependent β-thalassemia

On August 17 2022, the US Food and Drug Administration (FDA) approved the first cell-based gene therapy, betibeglogene autotemcel (beti-cel),…

Highlights in lymphoid malignancies from EHA 2022

VJHemOnc is excited to bring you the latest research updates in lymphoid malignancies from the EHA 2022 Congress, which took…

Approval of axi-cel in second-line for R/R LBCL & label update

Axicabtagene ciloleucel (axi-cel) was approved by the FDA in October 2017 for patients with large B-cell lymphoma (LBCL) after two…

Ciltacabtagene autoleucel receives FDA approval for R/R multiple myeloma

The U.S. Food and Drug Administration (FDA) has approved the use of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed chimeric antigen receptor…

Highlights from the EBMT-EHA CAR T-cell 2022 Meeting

VJHemOnc is excited to bring you the latest research updates in CAR-T therapy from the EBMT-EHA 4th European CAR T-cell…

Brexucabtagene autoleucel receives FDA approval for R/R B-ALL

On October 1, 2021, the US Food and Drug Administration (FDA) approved the use of brexucabtagene autoleucel, an autologous CD19-directed…

IMW 2021: Heinz Ludwig and Hermann Einsele discuss meeting highlights

VJHemOnc is excited to bring insights from Maria Victoria-Mateos and Irene Ghobrial, as discussed at the 18th International Myeloma Workshop…

IMW 2021: myeloma updates with Maria-Victoria Mateos and Irene Ghobrial

VJHemOnc is excited to bring insights from Maria Victoria-Mateos and Irene Ghobrial, as discussed at the 18th International Myeloma Workshop…

Key trial updates from IMW 2021

VJHemOnc is excited to bring you the latest updates from 18th International Myeloma Workshop (IMW) 2021, which brought together leading…

CAR-T therapy updates for the treatment of B-ALL

The introduction of chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) has significantly…

EHA 2021: key highlights in lymphoid malignancies

The 26th Congress of the European Hematology Association (EHA) 2021, which was held virtually from 9-17 of June, 2021, offered…

Highlights from the EBMT 2021 virtual meeting

VJHemOnc is excited to bring you highlights from the 47th Annual Meeting of the European Group for Blood and Marrow…

features: CAR-T & Cellular Therapy